



### Andrew P. Gilbert

Sócio

US CHAIR, CORPORATE PRACTICE  
GLOBAL CO-CHAIR, LIFE SCIENCES SECTOR

[andrew.gilbert@dlapiper.com](mailto:andrew.gilbert@dlapiper.com)

#### New Jersey (Short Hills)

T: +1 973 520 2553

F: +1 973 520 2573

M: +1 908 400 2105

Andrew Gilbert focuses his practice on corporate finance transactions, mergers and acquisitions and securities law matters. He represents public and private companies primarily in the technology, life sciences and healthcare industries, as well as investment firms that serve these sectors.

Andrew brings clients his extensive background representing issuers, underwriters, and venture capital firms in both public and private offerings. He is highly experienced in securities law compliance and corporate governance matters, with transactional experience in IPOs, PIPEs, registered direct offerings and direct follow-on offerings; as well as in venture capital, private equity, mergers and acquisitions, and other strategic transactions. He also has counseled numerous entrepreneurs and emerging growth companies in planning profitable liquidity strategies. Andrew regularly serves as outside general counsel for private and public companies at various stages of development.

Andrew is a member of the firm's National Leadership group of the US Emerging Growth and Venture Capital practice.

- Societário
- Fusões e Aquisições
- Crescimento Emergente e Capital de Risco
- Empresas Pública e Governança Corporativa
- Mercados de capitais
- Capital Privado

- Energia
- Ciências da Vida
- Tecnologia

## Admissões

- New Jersey
- Pennsylvania

## Reconhecimentos

- *Chambers USA*

- Band 1, New Jersey Corporate/M&A (2021-2022)  
Chambers comments, "*Andrew Gilbert represents companies from a range of industries in business sales, acquisitions and other corporate and financing matters.*" Clients say, "*He is very knowledgeable and can provide insight into the main issues of a deal and how to get them resolved.*" "*He is practical and oriented toward getting transactions done.*" "*An outstanding lawyer in all respects - I am continually amazed at his expertise.*" "*Andrew is an incredibly capable securities and governance guru.*"
- *The Legal 500 United States*
  - Recommended, Healthcare: Life Sciences (2020-2022)  
*The Legal 500* comments, "Fellow co-head Andrew Gilbert, on the transactional side, with deep experience in M&A, public and private offerings, and investment deals."
  - Recommended, Venture Capital & Emerging Companies (2018-2019)
- Roi-nj.com – Technology Influencer (April 2022)
- Recognized in *The Best Lawyers in America* and as a New Jersey Super Lawyer in every year since 2008
- Named to NJBIZ's Top 40 under 40 list (2003)
- *The M&A Atlas Awards*, Pharma & Devices Deal of the Year, Winner 2016: Tribute Pharmaceuticals Canada merger with POZEN (Aralez Pharmaceuticals)
- *The M&A Atlas Awards*, Outstanding M&A Law Firm of the Year Finalist 2016: DLA Piper
- Winner of the New Jersey Technology Council's 2016 Legend of Technology Award
- Financial Services Deal of the Year Award (over US \$100 million) from M&A Advisor in the representation of LLR Partners in the acquisition of CompoSecure, LLC, a leading designer and manufacturer of proprietary financial cards (2015)

For more information, pursuant to New Jersey Lawyer Advertising guidance, please [click here](#).

## Experiência anterior

Prior to joining DLA Piper, Andrew was a partner at an international law firm. Before attending law school, he served as an intern with the NASDAQ trading and corporate bond departments at Shearson Lehman Brothers Inc. and worked as an underwriter for American International Group (AIG). At AIG, Andrew underwrote professional liability and directors' and officers' legal liability insurance policies for several financial services companies.

## Formação

- J.D., Rutgers University School of Law 1993  
Research Editor, *Rutgers Computer and Technology Law Journal*
- B.A., Colgate University 1988

## Associações Profissionais

- Director, New Jersey Technology Council

## INSIGHTS

---

### Publicações

- "How To Navigate Pharma Collaboration And Licensing Agreements," *Life Science Leader*, February 1, 2017
- "The Facebook Effect Continues: SEC Approves Social Media for Corporate Announcements," *DLA Piper Capital Markets and Corporate Governance Alert*, April 2013

### Eventos

### Próximos

## The current state of life sciences transactions

9 January 2022  
San Francisco

---

## Anteriores

### The current state of life sciences financing

2 March 2021 | 3:00 - 4:00 EST  
Webinar

---

## NOTÍCIAS

---

### DLA Piper represents Intercept Pharmaceuticals, Inc. in US\$450 million deal to sell Ocaliva to Advanz Pharma outside the US

6 May 2022

DLA Piper is representing Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) – a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases – in its deal to sublicense to Advanz Pharma the rights to commercialize Ocaliva® (obeticholic acid) outside of the US, and sell certain foreign subsidiaries and rights regarding Intercept’s international operations.

---

### DLA Piper advises Jeeves in its US\$180 million Series C financing

19 April 2022

DLA Piper represented Jeeves, the all-in-one corporate card and expense management platform for global startups, in its US\$180 million Series C funding at a valuation of \$2.1 billion.

---

### William Mulholland joins DLA Piper’s Patent Prosecution practice in Phoenix

15 November 2021

DLA Piper announced today that William Mulholland has joined the firm’s Patent Prosecution practice and Life Sciences sector as a partner in Phoenix.

---

### DLA Piper advises TrueFort in US\$30 million Series B financing

23 September 2021

DLA Piper represented TrueFort, the zero trust application protection company, in a US\$30 million Series B funding round led by Shasta Ventures, with participation from Canaan and existing investors Evolution Equity Partners, Lytical Ventures and Emerald Development.

---

### **DLA Piper advises Jeeves in US\$57 million Series B financing**

21 September 2021

DLA Piper represented Jeeves Inc., an innovative expense management platform for fast-growing companies in global markets, in a US\$57 million Series B funding round led by CRV with participation by prior lead investor Andreesen Horowitz and other investors.

---

### **DLA Piper advises Overhaul in US\$35 million Series B financing**

21 September 2021

DLA Piper represented supply chain technology company Overhaul Group, Inc. in a US\$35 million Series B funding round. The round was led by Macquarie Capital, with participation from Edison Partners and Avanta Ventures, the venture arm of CSAA Insurance Group.

---

### **DLA Piper advises Katapult in merger with FinServ Acquisition Corp.**

15 June 2021

DLA Piper represented Katapult Holdings, Inc. in its merger with special purpose acquisition company FinServ Acquisition Corp.

---

### **DLA Piper LLP (US) announces new firm and practice leadership positions**

8 March 2021

DLA Piper LLP (US) is pleased to announce a number of firm and practice leadership changes.

---

### **DLA Piper advises Analytical Graphics in its US\$700 million sale to Ansys, Inc.**

3 December 2020

DLA Piper represented Analytical Graphics, Inc. (AGI) in its US\$700 million sale to Ansys, Inc.

---